  | Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y  Peer Reviewed verified by ORBi |
 | Soumoy, L., Ghanem, G. E., Saussez, S., & Journe, F. (October 2022). Bufalin for an innovative therapeutic approach against cancer. Pharmacological Research, 184, 106442. doi:10.1016/j.phrs.2022.106442 Peer Reviewed verified by ORBi |
Soumoy, L., Wells, M., Najem, A., Krayem, M., Ghanem, G., Hambye, S., Saussez, S., Blankert, B., & Journe, F. (12 September 2022). Uncovering the antiproliferative potential of toad venoms on metastatic melanoma [Poster presentation]. 12th International Symposium of Drug Analysis 32nd International Symposium on Pharmaceutical and Biomedical Analysis, Mons, Belgium. Peer reviewed |
 | Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journe, F., & Ghanem, G. E. (29 March 2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11 (7), 1157. doi:10.3390/cells11071157 Peer Reviewed verified by ORBi |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (07 December 2021). Bufalin to fight persister cells and breakdown resistance to targeted therapies in metastatic melanoma [Poster presentation]. EACR-AstraZeneca Virtual Conference 'Drug Tolerant Persister Cells', . |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (03 December 2021). Targeting tumor cell metabolic plasticity to breakdown resistance to targeted therapies in metastatic melanoma [Paper presentation]. ESPCR-2021, Virtual, Unknown/unspecified. |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (10 June 2021). Evaluating metabolic reprogramming in metastatic melanoma with resistance to targeted therapies to assess new targets for treatment [Poster presentation]. EACR-2022, Virtual, Unknown/unspecified. |
Gheysen, L., Soumoy, L., Trelcat, A., Verset, L., Journe, F., & Saussez, S. (2021). New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer. Cells. |
 | Soumoy, L., Wells, M., Ahmad, N., Krayem, M., Ghanem, G., Hambye, S., Saussez, S., Blankert, B., & Journe, F. (2020). 'Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms'. Biology, (9), 218-234. Peer reviewed |
 | Soumoy, L., Schepkens, C., Krayem, M., Ahmad, N., Tagliatti, V., Ghanem, E. G., Saussez, S., Colet, J.-M., & Journe, F. (22 May 2020). Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers, 12 (5), 12-23. doi:10.3390/cancers12051323 Peer reviewed |
Wells, M., & Soumoy, L. (03 February 2020). Évaluation in vitro des activités antiprolifératives et cytotoxiques d'extraits de venins de crapauds sur des lignées cellulaires de mélanome [Paper presentation]. Séminaire 'Kangourou' de l'Institut Santé, Mons, Belgium. |
Soumoy, L., Trelcat, A., Schepkens, C., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (31 January 2020). Metabolic switch in melanoma cells with acquired resistance to targeted therapies [Poster presentation]. BACR Annual meeting, Jette, Belgium. |
Soumoy, L., Trelcat, A., Schepkens, C., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (31 January 2020). Metabolic switch in melanoma cells with acquired resistance to targeted therapies [Poster presentation]. 14th meeting of the FRS-FNRS Contact group on Oxidative Proceses and Antioxidants, UMONS, Belgium. |
Wells, M., Soumoy, L., Journe, F., Saussez, S., Hambye, S., & Blankert, B. (04 December 2019). Bio-guided fractionation for the isolation of antiplasmodial and cytotoxic compounds from the venom of Bufo toads [Paper presentation]. 26ème RT-SFET, Paris, France. Peer reviewed |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (25 October 2019). Mechanisms of resistance in melanoma cells and the role of Mnk proteins in these processes [Poster presentation]. 4th symposium of the ULB-cancer research center, Brussels , Belgium. |
Soumoy, L., Najem, A., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (06 September 2019). Mechanisms of resistance in melanoma cells and the role of Mnk proteins in these processes [Paper presentation]. EDT-Cancerology Annual Meeting 2019, UCLouvain, Belgium. |
Gheysen, L., Descamps, G., Seminerio, I., Furgiuele, S., Soumoy, L., & Trelcat, A. (2019). Wonder Researchers , Communication audiovisuelle, Journée des doctorants, Mons, 2019. |
 | Soumoy, L., Kindt, N., Ghanem, G., Saussez, S., & Journe, F. (2019). Role of Macrophage Migration Inhibitory Factor (MIF) in melanoma. Cancers. Peer reviewed |
Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (05 March 2019). New combinations of targeted therapies in melanoma [Poster presentation]. Mardi des Chercheurs, Mons, Belgium. |
 | Soumoy, L., Krayem, M., Tagliatti, V., Ghanem, G., Saussez, S., & Journe, F. (01 February 2019). New combinations of targeted therapies in melanoma [Poster presentation]. BACR Annual meeting, Antwerpen, Belgium. |